
Adam J. Fein, Ph.D.
Drug Channels Institute

October 2018

Full report available at https://drugch.nl/wholesale
This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.


The complete End User License Agreement is available at: https://drugch.nl/2018-19-EULA

Please contact us at admin@drugchannels.net if you would like to upgrade the license anytime after purchase. You will pay only the difference in license fee.
ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the CEO of Drug Channels Institute (DCI), a leading management educator for and about the pharmaceutical industry. DCI is a subsidiary of Pembroke Consulting, Inc.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, The Washington Post, Forbes, and many others.

His popular and influential Drug Channels website is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. Drug Channels is the only place where you’ll find a serious discussion of PBMs, drug pricing, and pharmacy economics, all explained with humor and a healthy dose of pop culture.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
Adam J. Fein, Ph.D.
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.DrugChannelsInstitute.com
Email: afein@drugchannels.net

Visit Dr. Fein’s Drug Channels blog for the latest industry updates!
ABOUT DRUG CHANNELS INSTITUTE

Drug Channels Institute (DCI) is a leading provider of specialized management education for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as this 2018-19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—into comprehensive, interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. These online learning tools explain highly complex economic and business data and concepts so you can:

- Make better decisions to achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

View a module list at http://drugchannelsinstitute.com/products/e-learning-modules/.

DCI can code and brand any module for your company’s internal Learning Management System. Or you can get started quickly by letting us host your team via our online e-learning portal. DCI’s hosted e-learning modules are instantly viewable on all computer platforms, including iPads.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannelsinstitute.com
INTRODUCTION AND GUIDE TO THE 2018-19 REPORT

For pharmaceutical wholesalers, 2018 has been volatile and challenging. These companies have been confronting a diverse set of significant business, political, and legal challenges:

- Regulators, lawmakers, investors, and payers are closely and publicly scrutinizing the profit models of drug channel intermediaries
- List prices for brand-name drugs are growing at historically slow rates, pressuring a core economic driver of wholesalers’ profits
- Deflation in generic drug prices continues, though the rate of decline is slowing as inflationary excesses are squeezed out of the market
- The largest specialty pharmacies are using their leverage over wholesalers to extract additional pricing concessions
- The impact of regulatory changes to the Medicare Part B program and the 340B Drug Pricing Program on wholesalers’ business in the buy-and-bill market is not yet known
- Biosimilars are not delivering additional profits for wholesalers and seem unlikely to do so in the near future
- Amazon has made a major investment in the U.S. drug channel, creating uncertainty about its intentions and the potential for industry disruption
- Each large wholesaler is encountering challenges with diversification efforts: AmerisourceBergen with its compounding services, Cardinal Health with its medical products manufacturing, and McKesson with its international distribution and pharmacy businesses
- Wholesalers are facing fresh Congressional inquiries and additional lawsuits over their role in the distribution of opioids

We project that U.S. drug distribution revenues for the Big Three public wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—will reach $453 billion in 2018. However, gross margin for drug distribution will decline for the fourth straight year, though the reduction in gross profits is being moderated by ongoing revenue growth.

This 2018–19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our ninth edition—will help you understand these forces of change. I thoroughly update our annual exploration into the industry’s interactions with—and services for—other participants in our healthcare system. This definitive, nonpartisan resource remains the most comprehensive tool for analyzing the economic and business realities of U.S. pharmaceutical distribution.

The report synthesizes a wealth of statistical data, research studies, financial information, and my own business consulting experience. This unique resource will benefit pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and many others.
Structure of the 2018-19 Report

The 2018-19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors analyzes the industry in three major sections, comprising nine total chapters. It provides an up-to-date, fact-based analysis of this dynamic industry and how it works. This year’s report retains the structure that we used in last year’s edition, and the chapters correspond to those of previous editions. Some sections and chapters have been expanded or reorganized to better cover the latest industry developments.

We have updated all market and industry data with the most current information available. This 2018-19 edition contains the latest financial data and market positions of the largest public companies: AmerisourceBergen, Cardinal Health, and McKesson. It updates our annual analysis of each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models. This information allows you to assess differences among the public wholesalers’ business organizations, strategies, and financial performance.

Here are some of the notable updates in this 2018-19 report:

- Financial data for AmerisourceBergen and McKesson have been restated, based on the new reporting structures that these two companies have introduced since the previous edition of this report
- The report addresses emerging trends, including Amazon’s entry into the drug channel, the new drug pricing policies of the U.S. Department of Health and Human Services, and regulatory changes to the Medicare Part B program
- We provide new estimates for each company’s market share in the distribution of specialty drugs
- We include expanded information on numerous topics, including specialty distribution, the U.S. hospital market, McKesson’s non-U.S. businesses, generic drugs, and more

Here is a summary of the report’s main sections and chapters:

**PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES** provides an integrated overview of the major themes that recur throughout our analysis. Each theme includes links to relevant chapters and sections within the full report.

**SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS**

- **Chapter 1: Industry Overview** (page 7) defines the industry, describes business differences between full-line wholesaling and specialty distribution, summarizes wholesalers’ obligations under the Drug Supply Chain Security Act (DSCSA), explains wholesalers’ channel
roles, discusses and quantifies the products that wholesalers sell, and identifies the major industry participants and their revenues.

- **Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies** (page 26) analyzes the pharmacy market—the customer group that accounts for the majority of wholesalers’ revenues. It covers wholesalers’ services for smaller pharmacies, wholesalers’ participation in the pharmacy-PBM relationship via Pharmacy Services Administrative Organizations (PSAOs), and interactions with pharmacy buying groups. The chapter then analyzes how wholesalers work with larger pharmacies, including our updated exclusive analysis of the large generic sourcing consortia between wholesalers and the largest pharmacies. **Section 2.4.** (page 50) analyzes wholesalers’ role in the distribution of patient-administered drugs that specialty pharmacies dispense. We also consider wholesaler-owned specialty pharmacies.

- **Chapter 3: Channel Role for Physician Office/Clinics and Hospitals** (page 56) examines channels for provider-administered medications, explains the buy-and-bill system for drugs administered in outpatient settings, and describes the role and functions that wholesalers perform for hospitals, including hospitals that participate in the 340B Drug Pricing Program. This chapter also provides an in-depth consideration of group purchasing organizations (GPOs) for both hospitals and physician practices.

**SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS**

- **Chapter 4: Wholesaler Profitability** (page 83) delves into the industry’s income statement economics to explain the underlying sources of drug distribution profits. We deconstruct buy-side and sell-side gross margin components, distinguish sell-side profits from specialty and traditional drugs, and explain distribution service agreements (DSAs) with manufacturers. We analyze overall gross margins and operating profits. This chapter also explains how brand-name drug price inflation affects wholesalers’ profits.

- **Chapter 5: Financial Stability and Cash Management** (page 108) provides a detailed analysis of the key metrics that illustrate wholesalers’ overall financial health. These include capital structures, debt (leverage), balance sheet assets, cash flow, return on invested capital, and stock market valuation and performance.

- **Chapter 6: Forces of Change for Drug Distribution** (page 122) updates our analysis of key industry trends that will impact the market structure and economics of the pharmaceutical wholesaling and specialty distribution industries.

**SECTION III: BIG THREE WHOLESALER COMPANY PROFILES**

In this section, we analyze the latest financial data and strategies of the largest public companies. Each chapter provides parallel examinations of the Big Three public wholesalers.
We scrutinize each company’s business history, acquisitions and divestitures, business mix, profitability, largest customers, and company-specific business trends.

- Chapter 7: AmerisourceBergen Corporation (page 157)
- Chapter 8: Cardinal Health (Page 176)
- Chapter 9: McKesson Corporation (page 187)

How to Use the 2018-19 Report

The chapters are self-contained and do not need to be read in order. We include extensive internal references to help you navigate the entire document and customize it to your specific needs. There are nearly 400 endnotes, most of which have hyperlinks to original source materials. The report also includes a list of the Acronyms and Abbreviations (page 206) used within it.

Please note that highlighted internal references are clickable hyperlinks in the PDF document. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: ALT+Left Arrow
- Mac: Command+Left Arrow

To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- Windows: Shift+CTRL+F
- Mac: Shift+Command+F

As always, I welcome your feedback. Please contact me if you have any questions or comments about The 2018-19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Adam J. Fein
October 2018

P.S. You can find post-publication errata here: https://drugch.nl/2018-19-errata
## CONTENTS

PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES ................................................................. 1

SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS .................................................. 6

Chapter 1: Industry Overview ........................................................................................................ 7

1.1. Wholesale Industry Fundamentals ....................................................................................... 7
    1.1.1. Defining Drug Wholesale Distribution ........................................................................... 7
    1.1.2. Full-Line Wholesalers .................................................................................................... 8
    1.1.3. Specialty Distributors .................................................................................................... 10
    1.1.4. Regulation and Supply Chain Security ......................................................................... 12

1.2. The Products That Wholesalers Sell ...................................................................................... 14
    1.2.1. Brand vs. Generic Drugs ............................................................................................... 14
    1.2.2. Route of Administration ............................................................................................... 15
    1.2.3. Specialty vs. Traditional Drugs ..................................................................................... 16

1.3. Overview of Wholesalers’ Channel Roles ............................................................................. 16
    1.3.1. Physical Distribution .................................................................................................... 17
    1.3.2. Financial Intermediation ............................................................................................... 18
    1.3.3. Services for Pharmacies, Providers, and Manufacturers ............................................. 19
    1.3.4. Impact on Pharmacy and Provider Reimbursement .................................................... 20

1.4. Industry Participants ........................................................................................................... 20
    1.4.1. Big Three Wholesalers: Revenue and Growth Trends ................................................ 20
    1.4.2. Specialty Product Distribution Market Share ............................................................. 22
    1.4.3. Other Wholesale Market Participants ......................................................................... 24

Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies ............................................. 26

2.1. The Pharmacy Market ........................................................................................................ 27
    2.1.1. Outpatient Dispensing Formats .................................................................................... 27
    2.1.2. Pharmacy Market Size and Structure ......................................................................... 29

2.2. Independent Pharmacies .................................................................................................... 30
    2.2.1. Industry Position and Wholesaler Market Shares ....................................................... 31
    2.2.2. Wholesaler Services for Independent Pharmacies ..................................................... 33
    2.2.3. Franchise Programs and Marketing Groups ................................................................. 35
    2.2.4. PSAOs and the Wholesalers’ Role in the Pharmacy-Payer Relationship ..................... 36
    2.2.5. Pharmacy Group Purchasing Organizations and Wholesaler Relationships ............. 41
2.2.6. Wholesaler Generic Source Programs for Smaller Pharmacies ...................................................... 43
2.3. Retail Chains and Mail Pharmacies ........................................................................................................ 44
  2.3.1. Wholesale Suppliers to Largest U.S. Pharmacies ............................................................................. 44
  2.3.2. Physical Distribution Relationships Between Wholesalers and Retail Chains ................................ 45
  2.3.3. Generic Sourcing Relationships Between Wholesalers and Large Pharmacies ............................ 47
2.4. Specialty Pharmacies .............................................................................................................................. 50
  2.4.1. Specialty Pharmacy Market Participants ....................................................................................... 50
  2.4.2. Wholesalers’ Specialty Pharmacies ............................................................................................... 52
  2.4.3. Wholesalers’ Role in Manufacturer-Defined Limited Specialty Networks ........................................ 53
Chapter 3: Channel Role for Physician Offices/Clinics and Hospitals ............................................................ 56
  3.1. The Provider-Administered Drug Market ............................................................................................... 56
    3.1.1. Spending and Sites of Care .......................................................................................................... 56
    3.1.2. The Buy-and-Bill System ............................................................................................................ 59
    3.1.3. Group Purchasing Organizations (GPOs) .................................................................................. 60
    3.1.4. Contract Management and Chargebacks .................................................................................... 61
  3.2. Provider Reimbursement in the Buy-and-Bill System ........................................................................... 62
    3.2.1. Medicare Part B ......................................................................................................................... 62
    3.2.2. Commercial Health Plans ......................................................................................................... 64
  3.3. Physician Offices ................................................................................................................................ 66
    3.3.1. Pharmaceutical Purchasing and Distributors’ Services ............................................................... 66
    3.3.2. GPOs for Physician Practices ..................................................................................................... 68
    3.3.3. Specialty Drug Dispensing by Physician Practices .................................................................. 69
  3.4. Hospitals ............................................................................................................................................. 72
    3.4.1. Pharmaceutical Purchasing and Wholesalers’ Services ............................................................... 72
    3.4.2. Hospital GPOs .......................................................................................................................... 76
    3.4.3. Specialty Pharmacies at Hospitals and Health Systems .............................................................. 77
    3.4.4. Wholesalers and the 340B Drug Pricing Program ..................................................................... 79
SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS ................................................................ 82
Chapter 4: Wholesaler Profitability .............................................................................................................. 83
  4.1. Sources of Wholesaler Gross Profits and Gross Margin ...................................................................... 83
  4.2. Components of Buy-Side Gross Margin ............................................................................................... 84
    4.2.1. Distribution Service Agreements ............................................................................................... 85
Chapter 6: Forces of Change for Drug Distribution

6.2. Evolution of Pharmacy Dispensing Channels

6.1. The Outlook to 2022

5.6. Stock Market Performance

5.5. Return on Invested Capital

5.4. Uses of Cash

5.3. Cash Conversion Cycle

5.2. Balance Sheet Assets

5.1. Debt, Coverage, and Liquidity Ratios

Chapter 5: Financial Stability and Cash Management

4.7. Operating Expenses and Operating Profit

4.6. The Profit Impact of Brand-Name Drug Price Inflation

4.5. Gross Profits of Brand vs. Generic Drugs

4.4. Estimates of Overall Buy-Side and Sell-Side Gross Margins

4.3. Sell-Side Gross Margins and Cost-Minus Discounts

4.2. Payment Discounts

4.2.3. Specialty Distribution Service Agreements

4.2.2. Payment Discounts

4.2.1. Payment Discounts

4.2.0. Payment Discounts

4.1.x Economic Report on Pharmaceutical Wholesalers and Specialty Distributors


4.1.7. Economic Report on Pharmaceutical Wholesalers and Specialty Distributors


4.1.5. Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

4.1.4. Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

4.1.3. Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

4.1.2. Economic Report on Pharmaceutical Wholesalers and Specialty Distributors


4.1.0. Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Chapter 4: Costs and Profits

4.6. Inventory Appreciation and Revaluation

4.6.5. Wholesaler Compensation and Bona Fide Service Fees

4.6.4. Generic Sourcing Formularies

4.6.3. Specialty Distribution Service Agreements

4.6.2. Payment Discounts

4.6.1. Brand

4.5.3. Private Label Generic Drugs

4.5.2. Lifecycle Profits for Provider

4.5.1. Lifecycle Profits for Traditional Generic Drugs

4.4.5. Bulk Purchase Discounts

4.4.4. Bid Discounts

4.4.3. Competitive Bidding

4.4.2. Special Purchase Discounts

4.4.1. Fixed Percentage Discounts

4.4.0. Wholesale Prices

Chapter 3: Cost and Productivity Metrics

3.2.1. Accounts Payable and Days Payable Outstanding

3.2.2. Accounts Receivable and Days Sales Outstanding

3.2.3. Inventory Levels and Days Inventory Outstanding

3.1. Stock Management and Turnover

3.1.1. Inventory Management

3.1.0. Inventory Management

Chapter 2: Costs and Profits

2.2. Brand

2.1. Generic

Chapter 1: Introduction

1.1. The Outlook for U.S. Pharmaceutical Purchases and Wholesaler Revenues

1.2. The Outlook for Brand-Name Drug Prices

1.3. The Outlook for Generic Drug Prices

1.4. Drug Channel Disruption and Potential Changes to Wholesaler Compensation

1.5. Evolution of Pharmacy Dispensing Channels
LIST OF EXHIBITS

Exhibit 1: Full-Line Wholesale Revenues, by Type of Customer, 2016 ................................................................. 9
Exhibit 2: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2016 ................................. 9
Exhibit 3: Full-Line Wholesalers, Inventory Levels and Product Sales, by Product Type, 2010 vs. 2016 .......... 10
Exhibit 4: Specialty Distributor Revenues, by Type of Customer, 2016 ................................................................. 11
Exhibit 5: Specialty Distributor Sales, by Therapeutic Area, 2016 ........................................................................ 11
Exhibit 6: Distribution Center Operational Metrics, Full-Line Wholesalers vs. Specialty Distributors, 2017 .... 12
Exhibit 7: Timeline of DSCSA Requirements for Wholesale Distributors, 2013 to 2023 ................................. 12
Exhibit 8: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2002 to 2022 .................................. 15
Exhibit 9: Allowance for Doubtful Accounts at Big Three Wholesalers, by Company, 2018 ......................... 18
Exhibit 10: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, Calendar Year 2017 .... 21
Exhibit 12: Specialty Product Distribution Revenues, by Division and Parent Company, 2017 ................... 22
Exhibit 13: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient
Brand-Name Drugs ........................................................................................................................................ 26
Exhibit 14: Total U.S. Pharmacy Industry Revenues, Prescriptions, and Locations, by Dispensing Format, 2017 ............................................................... 29
Exhibit 15: Number of Independent Pharmacy Locations, 2001 to 2017 ......................................................... 31
Exhibit 16: Estimated Drug Sales and Market Share with Independent Pharmacies, by Wholesaler, 2017 ...... 33
Exhibit 17: U.S. Pharmacy Franchise and Marketing Programs, 2018 ............................................................... 35
Exhibit 18: Consumer Satisfaction with Wholesalers’ Pharmacy Group vs. Other Dispensing Formats, 2018 .. 36
Exhibit 19: Largest Pharmacy Services Administrative Organizations, by Members and Ownership, 2018 ...... 39
Exhibit 20: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Number of
Pharmacies, 2018 ................................................................................................................................. 42
Exhibit 21: Wholesaler Generic Source Programs, Number of SKUs and Manufacturers, 2011 to 2016 ......... 43
Exhibit 22: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers, 2018 ......................................... 44
Exhibit 23: Alignment Between the Big Three Wholesalers and the Top Five Pharmacies .......................... 45
Exhibit 24: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2017 ................................. 46
Exhibit 25: Share of U.S. Generic Purchasing Volume, by Organization, 2018 ................................................. 47
Exhibit 26: Specialty Drug Prescription Revenues, by Dispensing Format, 2017 ................................................. 50
Exhibit 28: Alternative Channels to Specialty Pharmacies in Limited Dispensing Networks ..................... 54
Exhibit 29: Medical Benefit Spending on Provider-Administered Drugs, by Drug Category and Payer, 2016 .. 57
Exhibit 30: Medicare Part B, Share of Spending, by Site of Care and Drug, 2016 .............................................. 57
Exhibit 31: Commercial Medical Benefit Spending for Outpatient Specialty Drugs, by Site of Care, 2011 vs.
2016 ..................................................................................................................................................... 58

Exhibit 63: Big Three Wholesalers, Distribution Operating Profits As a Percentage of Gross Profits, 2017 vs. 2018 ........................................................................................................................................107
Exhibit 64: Big Three Wholesalers, Total Short-Term and Long-Term Debt, 2018 .................................................................108
Exhibit 65: Big Three Wholesalers, Debt-to-EBITDA Ratio, FY2016 to FY2018 ........................................................................110
Exhibit 66: Big Three Wholesalers, Liquidity Ratios, FY2018 .................................................................................................110
Exhibit 67: Big Three Wholesalers, Composition of Current Assets, 2018 .................................................................111
Exhibit 68: Illustrative Wholesaler Cash Conversion Cycle for Brand-Name Drugs Sold to a Pharmacy Customer ........................................................................................................................................112
Exhibit 69: Big Three Wholesalers, Cash Conversion Cycle, 2018 .................................................................................................113
Exhibit 70: Big Three Wholesalers, Cash Conversion Cycle, 2013 to 2018 ........................................................................113
Exhibit 71: Big Three Wholesalers, Days of Sales in Inventory, 2013 to 2018 ........................................................................115
Exhibit 72: Percentage of Wholesalers’ Trade Accounts Receivable and DSO for Largest Customers, 2017/2018 ........................................................................................................................................116
Exhibit 73: Big Three Wholesalers, Days Payable Outstanding, 2013 to 2018 ........................................................................117
Exhibit 74: Big Three Wholesalers, Dividends and Share Repurchases As a Percentage of Operating Cash Flow, FY2016 to FY2018 ........................................................................................................................................118
Exhibit 75: Big Three Wholesalers, Return on Invested Capital, 2014 to 2018 ........................................................................119
Exhibit 76: Forward Price-to-Earnings Ratio, Big Three Wholesalers vs. S&P 500, 2014 to 2018 ........................................................................119
Exhibit 77: One- and Five-Year Stock Price Performance, Big Three Wholesalers vs. Manufacturers and Overall Market ........................................................................................................................................120
Exhibit 78: Total U.S. Drug Purchases, Annual Total, 2013 to 2022 .................................................................................................123
Exhibit 79: Average Year-Over-Year Change in Pricing of Mature Generic Drugs, 2014 to 2018 ........................................................................126
Exhibit 80: Change in List vs. Net Price, by Manufacturer, 2017 .................................................................................................129
Exhibit 81: Total Change in 30-Day Equivalent Prescriptions Dispensed and Drugs Purchases, by Pharmacy Format, 2012 to 2017 ........................................................................................................................................132
Exhibit 82: Pharmacy Industry Prescription Revenues, Traditional vs. Specialty Drugs, 2012 to 2022 ........................................................................133
Exhibit 83: Medicare Part B Spending on Provider-Administered Outpatient Drugs, by Location of Service, 2005 to 2016 ........................................................................................................................................138
Exhibit 84: Share of Medicare Part B Spending on Provider-Administered Outpatient Drugs, by Location of Service, 2005 to 2016 ........................................................................................................................................138
Exhibit 85: Percentage of Physician Practices Owned by a Hospital or Health System, by Medical Specialty, 2007 vs. 2017 ........................................................................................................................................139
Exhibit 86: Share of Specialty Distributor Revenues, by Customer Type, 2011 to 2016 ........................................................................142
Exhibit 87: Use of Site-of-Care Management Programs for Provider-Administered Drugs, Commercial Health Plans, 2013 to 2017 ........................................................................................................................................143
Exhibit 88: Health Plans’ Perceived Pricing Competitiveness for Specialty Drugs, by Site of Care, 2018 ..........144
Exhibit 89: Drug Sourcing for In-Practice Administration, by Source, 2010 vs. 2016 ........................................................................145
Exhibit 90: FDA Approved Biosimilars, 2015 to 2018 ........................................................................................................................................150
Exhibit 91: AmerisourceBergen, Pharmaceutical Distribution Segment, Profitability Metrics, 2014 to 2018
Exhibit 92: AmerisourceBergen, Estimated Revenues and Operating Profit, by Segment, FY2018
Exhibit 93: AmerisourceBergen, Top 10 U.S. Drug Distribution Customers, FY2018
Exhibit 94: Diplomat Pharmacy, Drug Purchases, by Supplier, 2012 to 2017
Exhibit 95: AmerisourceBergen, Revenues from Walgreens Boots Alliance, 2014 to 2018E
Exhibit 96: AmerisourceBergen, Days Sales Outstanding from Walgreens vs. All Other Customers, 2014 to 2018
Exhibit 97: AmerisourceBergen, Revenues from Express Scripts, 2014 to 2018E
Exhibit 98: Express Scripts, Pharmacy Dispensing Revenues and Share of Pharmaceutical Purchases Through AmerisourceBergen, 2014 to 2017
Exhibit 99: AmerisourceBergen, Revenues by Major Business Segment and Customer, FY2013 vs. FY2018
Exhibit 100: AmerisourceBergen Distribution Company, Revenues and Growth, 2014 to 2018:Q2
Exhibit 101: AmerisourceBergen Specialty Businesses, Revenues and Growth, 2013 to 2018E
Exhibit 102: Cardinal Health, Profitability Metrics, 2014 to 2018
Exhibit 103: Cardinal Health, Estimated Revenues and Operating Profit, by Segment, FY 2018
Exhibit 104: Cardinal Health, Top 10 U.S. Drug Distribution Customers, FY 2018
Exhibit 105: Cardinal Health, Revenues from CVS Health, 2014 to 2018
Exhibit 106: Cardinal Health, Days Sales Outstanding from CVS Health vs. All Other Customers, 2014 to 2018
Exhibit 108: McKesson, Distribution Businesses, Gross and Segment Operating Profitability Metrics, 2016 to 2018
Exhibit 109: McKesson, Estimated Revenues and Operating Profit, by Segment, FY 2018
Exhibit 110: McKesson, Top 10 U.S. Drug Distribution Customers, FY2018
Exhibit 111: McKesson, Revenues from CVS Health, 2014 to 2018
Exhibit 112: McKesson, Days Sales Outstanding from CVS Health vs. All Other Customers, 2014 to 2018
Exhibit 114: McKesson Health Mart, Store Count and Change, 2007 to 2018
Exhibit 115: McKesson Europe, Revenues and Profit, by Operating Segment, 2018
Exhibit 116: Celesio, Revenues, by Operating Segment, 2012 to 2018
Exhibit 117: McKesson Canada, Revenues and Growth, 2014 to 2018